SCHEMBL30779669

SCHEMBL30779669

O=P(O)(O)OCCCCSc1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.51
FDPS P14324 3/20 0.49
HDAC3 O15379 1/20 0.47
HDAC4 P56524 1/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC7 Q8WUI4 1/20 0.47
HDAC2 Q92769 1/20 0.47
HDAC10 Q969S8 1/20 0.47
HDAC11 Q96DB2 1/20 0.47
HDAC8 Q9BY41 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
HDAC9 Q9UKV0 1/20 0.47
HDAC5 Q9UQL6 1/20 0.47
MAPK1 P28482 1/20 0.47
LPAR3 Q9UBY5 3/20 0.43
LPAR1 Q92633 2/20 0.43
LPAR2 Q9HBW0 2/20 0.43
NPC1 O15118 2/20 0.42
RECQL P46063 1/20 0.42
RAB9A P51151 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8916434 0.79 HDAC1 (0.43) ALDH1A1FDPSHDAC3HDAC4HDAC1
SCHEMBL8918704 0.79 HDAC1 (0.43) ALDH1A1FDPSHDAC3HDAC4HDAC1
SCHEMBL8915912 0.77 HDAC1 (0.41) ALDH1A1FDPSHDAC3HDAC4HDAC1
SCHEMBL8915921 0.77 HDAC1 (0.41) ALDH1A1FDPSHDAC3HDAC4HDAC1
SCHEMBL8918712 0.77 HDAC1 (0.41) ALDH1A1FDPSHDAC3HDAC4HDAC1
SCHEMBL8918707 0.77 HDAC1 (0.41) ALDH1A1FDPSHDAC3HDAC4HDAC1
SCHEMBL420011 0.77 ALDH1A1 (0.78) ALDH1A1HDAC3HDAC4HDAC1HDAC7
SCHEMBL23051126 0.76 ALDH1A1 (0.56) ALDH1A1FDPSHDAC3HDAC4HDAC1
SCHEMBL22773976 0.75 KCNA3 (0.59) ALDH1A1FDPSHDAC3HDAC4HDAC1
SCHEMBL28947840 0.75 ALDH1A1 (0.50) ALDH1A1HDAC3HDAC4HDAC1HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250188055-A1 Acyl Sulfonamides that are BCL Family Antagonists for Use in Clinical Management of Conditions Caused or Mediated by Senescent Cells and for Treating Cancer UNITY BIOTECHNOLOGY, INC. 2025-06-12 US disclosed
US-12221433-B2 Acyl sulfonamides that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer UNITY BIOTECHNOLOGY, INC. (US) 2025-02-11 US disclosed
EP-4335516-A2 ACYL SULFONAMIDES THAT ARE BCL FAMILY ANTAGONISTS FOR USE IN CLINICAL MANAGEMENT OF CONDITIONS CAUSED OR MEDIATED BY SENESCENT CELLS AND FOR TREATING CANCER Unity Biotechnology, Inc. (US) 2024-03-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12221433-B2 Acyl sulfonamides that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer BCL2, MCL1, BAD ALDH1A1 2512/4885FDPS 1703/4885HDAC3 105/4885
US-20250188055-A1 Acyl Sulfonamides that are BCL Family Antagonists for Use in Clinical Management of Conditions Caused or Mediated by Senescent Cells and for Treating Cancer BCL2, MCL1, BAD ALDH1A1 2512/4885FDPS 1703/4885HDAC3 105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.